PRORSD1P: A Potential Drug Target and Biomarker (G344405)

Target Name: PRORSD1P

NCBI ID: G344405

PRORSD1P

PRORSD1P: A Potential Drug Target and Biomarker

Prorylendanumab, also known as PRORSD1P, is a drug that is being developed by companies such as AstraZeneca for the treatment of various diseases, including Alzheimer's disease. The drug is in the category of B-cell maturation antigens (BCMA), which are a type of protein that is found on the surface of certain types of cancer cells. By targeting these proteins, PRORSD1P is able to interact with and destroy cancer cells.

One of the main advantages of PRORSD1P is its ability to selectively target BCMA-positive cancer cells, such as those that are derived from breast cancer. This is because the protein that PRORSD1P targets is only present on the surface of these cells, and not on the surface of other types of cells. This allows for a highly targeted and effective treatment.

In addition to its ability to selectively target BCMA-positive cells, PRORSD1P is also known for its ability to induce apoptosis (programmed cell death) in cancer cells. This is because the protein that PRORSD1P targets is able to interact with and destabilize the mitochondria in these cells, which can cause them to undergo apoptosis. This can be a highly effective way to kill cancer cells, as it allows for the complete destruction of these cells without the need for toxic chemicals or other treatments.

Another potential advantage of PRORSD1P is its ability to be administered by intravenous (IV) infusion. This allows for the treatment to be administered in a non-invasive and comfortable manner, without the need for specialized equipment or training. This can be especially beneficial for patients who are experiencing symptoms related to cancer treatment, such as pain or nausea.

In addition to its potential use as a cancer treatment, PRORSD1P has also been shown to have potential applications in other areas. For example, the protein that PRORSD1P targets has also been shown to be present in the brains of individuals with Alzheimer's disease, and may be a potential target for the treatment of this disease. In addition, PRORSD1P has been shown to have potential applications in the treatment of other conditions, such as multiple sclerosis and autoimmune disorders.

Overall, PRORSD1P is a promising drug target and biomarker with a potential for the treatment of a wide range of conditions. Its ability to selectively target BCMA-positive cancer cells and induce apoptosis in these cells makes it an attractive candidate for cancer treatment. In addition, its ability to be administered by IV infusion makes it a convenient and comfortable treatment option for patients. Further research is needed to fully understand the potential applications of PRORSD1P and to determine its safety and effectiveness as a cancer treatment.

Protein Name: Prolyl-tRNA Synthetase Associated Domain Containing 1, Pseudogene

The "PRORSD1P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PRORSD1P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets